Avisi Technologies treats first patient in SAPPHIRE trial for glaucomaByMartin David HarpDecember 4th 2025
Inflammasome Therapeutics completes phase 2 trial enrollment for K8 in GAByMartin David HarpDecember 3rd 2025
FDA approves Amneal Pharmaceuticals' cyclosporine ophthalmic emulsion 0.05%ByMartin David HarpDecember 2nd 2025
The Art and Science of Presbyopia Correction: Navigating the IOL Patient JourneyByMatt Hoffman,Zach R. Balest, MD,Lisa K. Feulner, MD, PhDDecember 2nd 2025
Eydenzelt, Celltrion’s biosimilar referencing Eylea, approved in CanadaByMartin David HarpDecember 2nd 2025